Project Grant R01CA302874
Award Date
7/1/25
Completion Date
6/30/30
Dollars Obligated
$650K
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $693,880 in funding to the Fred Hutchinson Cancer Center in Seattle, WA to develop a new cancer treatment approach using engineered CD4+ T cells. The goal is to create CD4+ T cells that can specifically target the tumor microenvironment and activate other immune cells to attack solid tumors, particularly in patients with melanoma and other cancers resistant to current immunotherapies....
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $194,013.00 to the University of Southern California to develop a new therapeutic monoclonal antibody targeting isoaspartylated ELAVL4 protein for the treatment of small cell lung cancer (SCLC). The key objectives are to: 1) Generate a mouse monoclonal antibody specifically binding to isoaspartylated ELAVL4, which is expressed on the surface of SCLC tumors and can trigger an...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $1,001,029 to Immunova Therapeutics LLC for the development of a CD4 TCR-engineered T cell immunotherapy for the treatment of triple-negative breast cancer (TNBC). The award period runs from September 20, 2024 to August 31, 2026. The key products and services to be delivered under this grant include: Generation of a GMP-grade master cell bank and viral particles for the IMT-422 (CD4...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $1,013,623 to March Biosciences Inc. to develop dual-targeting chimeric antigen receptor (CAR) T-cell therapies for the treatment of relapsed and refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoma (TCL). The key objectives are to engineer partially-matched, donor-derived CAR T-cells targeting the CD5 and CD7 antigens, which are expressed on most T-cell...
This $399,499 Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports the development of Liquid Biotech's TELOMESCAN circulating tumor cell (CTC) assay for monitoring non-small cell lung cancer (NSCLC) patients undergoing radiation and immunotherapy. The key products and services to be delivered through this funding include: 1) Developing a clinical prototype of the TELOMESCAN assay with automated analysis to...
This federal Project Grant award of $399,669.00 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research program) aims to establish the feasibility of commercializing a personalized and multi-targeted adoptive T cell therapy (ATCT) for the treatment of glioblastoma (GBM), the most common and deadly primary brain cancer. The key products/services to be delivered under this award include: Developing a platform to generate potent and personalized GBM-specific T cells in an...
This $635,248 five-year Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) supports the development of a novel self-amplifying ribonucleic acid (SARNA) technology encoding a bispecific T-cell engaging (BiTE) antibody for the treatment of lung cancer. The key objectives are to: 1) design modified SARNA constructs expressing BiTE antibodies and evaluate their protein expression performance in vitro; 2) assess the in vitro/in vivo bioavailability and...
This $127,049 Project Grant award from the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) program supports research by Harvard Medical School to investigate the functional and spatial properties of tumor-specific, tumor-infiltrating CD8 T cells. The key objectives are to: Generate patient-derived xenograft (PDX) mouse models of melanoma to test the required diversity of T cell receptors (TCRs) from tumor-infiltrating T cells to control tumor growth. Use one of...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the Sloan-Kettering Institute for Cancer Research provides $402,600.00 to develop novel chimeric antigen receptor (CAR) T-cell therapies targeting the U5 small nuclear ribonucleoprotein (U5 snRNP) complex for the treatment of acute myeloid leukemia (AML). The key products and services to be delivered under this 5-year award include: Testing the efficacy and safety of CAR T-cells targeting the...
This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research program) provides funding of $647,632 to the University of California, Los Angeles (UCLA) to evaluate the impact of adding a transgenic tumor necrosis factor alpha (TNF-alpha) gene to T-cell receptor (TCR) or chimeric antigen receptor (CAR) therapies for solid tumors. The key objectives are to: Assess the anti-tumor efficacy and safety profile of the "TNF-alpha-armed" TCR/CAR-T cell...